Sarepta Therapeutics announced that a patient with Duchenne muscular dystrophy who received Elevidys (delandistrogene moxeparvovec-rokl) died following treatment.

Dietitian-supported intensive nutritional therapy improves survival and disease severity in patients with alcohol-related acute-on-chronic liver failure, a study finds.

March 25, 2025 expert reaction to study on first pig-to-human liver transplantation . A study published in Nature looks at a genetically modified pig-to-human liver transplantatio ...

Dr. Arvinder Singh Soin faced an ethical challenge when a 17-year-old girl arrived in a coma with acute liver failure.

Sarepta Therapeutics Inc.’s stock tumbled 23% on Tuesday after the biotech said a patient who used its gene therapy Elevidys for the rare disease ... has died of acute liver failure.

Shares of Sarepta Therapeutics have struggled for the past year due to concerns about the commercial potential of its gene ...

A young man treated with Elevidys died of acute liver failure. The case may give doctors pause before prescribing the ...

Sarepta Therapeutics said a patient taking its treatment for Duchenne muscular dystrophy has died from acute liver failure.

Sarepta Therapeutics said on Tuesday a young man has died due to acute liver failure after treatment with its gene therapy for a rare muscular dystrophy.

Why didn’t analysts share the same fear that gripped investors about Sarepta stock? One reason is the known risk of acute liver injury associated with adeno-associated virus vector (AAV)-based gene ...

Trial to assess intensive care liver support system across 13 UK centers, led by UCL, Royal Free, Kings College and Queen Elizabeth ...